DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Consensus Rating of “Hold” from Brokerages

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been given a consensus rating of “Hold” by the fourteen research firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $13.8182.

XRAY has been the topic of several recent research reports. Mizuho decreased their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Citigroup began coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Wells Fargo & Company increased their price objective on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Finally, Barrington Research increased their price objective on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, March 2nd.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY opened at $10.21 on Monday. The firm’s 50-day moving average price is $11.42 and its 200-day moving average price is $11.80. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -3.24, a P/E/G ratio of 1.21 and a beta of 0.93. DENTSPLY SIRONA has a 12-month low of $9.40 and a 12-month high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The business had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts anticipate that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Transactions at DENTSPLY SIRONA

In other news, Director James D. Forbes acquired 5,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Gregory T. Lucier acquired 15,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the transaction, the director directly owned 65,000 shares in the company, valued at $809,250. This trade represents a 30.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 70,000 shares of company stock worth $956,437 over the last three months. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter worth about $26,000. Eurizon Capital SGR S.p.A. bought a new position in DENTSPLY SIRONA in the 4th quarter worth about $26,000. Caitong International Asset Management Co. Ltd grew its stake in DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. Huntington National Bank grew its stake in DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 2,051 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.